Praluent Cost in North Dakota 2026

What Praluent Actually Costs in North Dakota Without Insurance

The cash price for Praluent at North Dakota retail pharmacies sits at approximately $580 per month in 2026, matching the Regeneron/Sanofi manufacturer list price. No meaningful pharmacy-level discount exists for uninsured patients paying full cash price without an assistance program. That $580 figure assumes the standard 75 mg or 150 mg prefilled pen dosed every two weeks, dispensed as a pack of two pens per monthly fill.

Alirocumab belongs to the PCSK9 inhibitor drug class. It works by binding PCSK9, a protein that degrades LDL receptors in the liver, preventing those receptors from clearing LDL cholesterol from circulation [1]. By blocking PCSK9, alirocumab raises functional LDL receptor density and drives LDL-C down by 45 to 60 percent depending on background statin therapy [2]. The FDA approved it in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering on maximally tolerated statin therapy [3].

At $580 per month, the annual cash burden reaches $6,960, which places Praluent out of reach for most uninsured North Dakotans. The 2024 median household income in North Dakota was approximately $73,000 [4], meaning the unassisted cash price consumes nearly 10% of median pre-tax income. This cost barrier is why understanding every available assistance pathway matters before paying list price.

Does North Dakota Medicaid Cover Praluent?

North Dakota Medicaid does not cover Praluent as of 2026. The ND Medicaid preferred drug list does not include alirocumab, and no non-preferred exception pathway with a clear approval track has been published by the North Dakota Department of Human Services for this agent [5]. Patients enrolled in ND Medicaid who need a PCSK9 inhibitor should discuss evolocumab (Repatha) separately with their prescriber, as formulary status can differ by drug within the same class.

The ACC/AHA 2022 guideline on the management of blood cholesterol states: "In patients with clinical ASCVD in whom LDL-C remains above 70 mg/dL on maximally tolerated statin therapy, the addition of ezetimibe and, if needed, a PCSK9 inhibitor is reasonable" [6]. That clinical need does not translate to Medicaid coverage in North Dakota. Dual-eligible patients (Medicare-Medicaid) may have a separate Medicare Part D pathway; see the next section.

Medicaid expansion in North Dakota covers adults up to 138% of the federal poverty level, but expanded Medicaid eligibility does not change the formulary exclusion for alirocumab [5]. Patients who are Medicaid-eligible and meet clinical criteria should ask their cardiologist or primary care provider to submit a prior authorization request with detailed clinical documentation. Approval remains uncommon but is not categorically impossible under an exceptions process.

Medicare Part D and Commercial Insurance Coverage in North Dakota

Most Medicare Part D plans and commercial insurance carriers in North Dakota require prior authorization (PA) and sometimes step therapy before covering Praluent. Step therapy typically demands documented failure or intolerance of at least one high-intensity statin, often with the addition of ezetimibe, before PCSK9 inhibitor coverage is approved [7].

The criteria most insurers apply mirror the FDA label: established ASCVD or HeFH diagnosis, LDL-C above a threshold (often 70 mg/dL for ASCVD or 100 mg/dL for HeFH), and current maximally tolerated statin therapy documented in the chart [3]. A prescriber who submits a PA without those three documented elements faces near-certain denial on first submission.

Once approved, out-of-pocket costs depend on plan tier placement. Praluent typically lands on specialty tier 4 or tier 5, with cost-sharing between 25 and 33 percent of the negotiated price. On a negotiated price of roughly $400 to $500, that produces a co-insurance cost of $100 to $165 per fill before the savings card is applied.

ODYSSEY OUTCOMES enrolled 18,924 patients with acute coronary syndrome and followed them for a median of 2.8 years. Alirocumab 75 mg (titrated to 150 mg if needed) reduced the primary endpoint of major adverse cardiovascular events by 15 percent relative to placebo (hazard ratio 0.85 to 95% CI 0.78 to 0.93, P<0.001) [2]. Insurers frequently cite this trial as the evidence base for coverage criteria.

How the Regeneron / Sanofi Praluent Savings Card Works in North Dakota

The Regeneron/Sanofi savings card (also called the Praluent Co-Pay Card) can reduce out-of-pocket cost to $0 per month for commercially insured North Dakota patients who qualify. The program is available at participating retail and mail-order pharmacies and does not require enrollment in a separate patient assistance program [8].

Eligibility rules: the patient must have commercial (private) insurance, must not be enrolled in a federal or state government insurance program including Medicare, Medicaid, or CHIP, and must be a U.S. resident. North Dakota residents who meet those criteria can activate the card at PraluentSavings.com or by calling the program number on the Regeneron patient support line.

The card covers the gap between the insurer's negotiated price and the patient's co-pay or co-insurance, up to a program annual maximum. Patients should confirm the current annual cap directly with the program because it has changed between program years. At $0 per month with the card active, the savings card effectively eliminates the cost barrier for commercially insured ND patients who have already cleared prior authorization.

Patients without commercial insurance, including those on ND Medicaid or Medicare Part D, cannot use the co-pay card. They may instead apply to the Praluent patient assistance program (PAP), which provides free medication to qualifying low-income uninsured or underinsured patients [9]. Income thresholds for the PAP are updated annually; applicants submit financial documentation through the Regeneron Genetics Center patient support portal.

Compounded Alirocumab in North Dakota: Legality and Access

Compounded alirocumab through a licensed 503A compounding pharmacy is legal in North Dakota. Under federal law, 503A compounding pharmacies may prepare patient-specific compounds when a commercially available drug is not appropriate for an individual patient and the prescriber provides a valid prescription with a documented clinical rationale [10]. North Dakota does not impose a state-level prohibition beyond the federal 503A framework.

Compounded alirocumab can cost significantly less than the $580 per month brand price, depending on the compounding pharmacy and the formulation. Some 503A pharmacies that operate in North Dakota or ship to ND residents price compounded PCSK9 inhibitor formulations at a fraction of brand cost, though pricing varies and patients should obtain quotes directly from the dispensing pharmacy.

The FDA has not approved any compounded version of alirocumab. Compounded preparations are not bioequivalent-tested against Praluent and are not covered by the Regeneron/Sanofi savings card. The clinical evidence base for alirocumab, including ODYSSEY OUTCOMES [2] and ODYSSEY LONG TERM [11], was generated entirely with the brand formulation. A prescribing clinician who recommends compounded alirocumab should document the clinical rationale, typically cost-related inability to access the brand drug, in the medical record.

Telehealth prescribers licensed in North Dakota may write a 503A compound prescription for a North Dakota patient. North Dakota participates in the Interstate Medical Licensure Compact, which allows physicians licensed in multiple states to prescribe via telehealth across state lines under a single compact license [12]. Patients consulting a telehealth provider about compounded alirocumab should confirm the provider holds an active North Dakota license before the consultation.

HealthRX Cost Navigation Framework for North Dakota Alirocumab Patients

Use this decision sequence before paying list price:

1. Commercially insured and under 65: Apply the Regeneron/Sanofi savings card first. Potential cost: $0/month.
2. Medicare Part D: Savings card ineligible. Submit PA with full clinical documentation. If denied, appeal with ACC/AHA guideline language from the 2022 cholesterol management update [6].
3. ND Medicaid: Coverage not available on formulary. Request a prescriber-submitted exception with ASCVD/HeFH diagnosis codes, LDL-C lab values, and statin trial documentation.
4. Uninsured / underinsured: Apply to the Praluent PAP for free brand drug [9], or obtain a telehealth prescription for compounded alirocumab via a licensed 503A pharmacy.
5. All pathways exhausted: Ask the prescriber whether evolocumab (Repatha) has different formulary status on the specific plan; inclisiran (Leqvio), dosed twice annually, may have different cost-sharing under some plans [13].

The Clinical Case for Alirocumab: Why Patients Pursue It Despite Cost

Alirocumab's LDL-C reduction of 45 to 60 percent on top of statin therapy translates into meaningful cardiovascular event reduction for high-risk patients [2]. The ODYSSEY OUTCOMES trial showed that patients with baseline LDL-C above 100 mg/dL derived the largest absolute benefit, with a number needed to treat of approximately 16 over 2.8 years to prevent one major cardiovascular event [2]. That number becomes clinically decisive for cardiologists managing patients with recent acute coronary syndrome.

The ACC/AHA 2022 cholesterol guideline gives PCSK9 inhibitors a Class IIa, Level of Evidence A recommendation for patients with clinical ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe [6]. "For very high-risk ASCVD patients," the guideline states, "it is reasonable to add a PCSK9 inhibitor" when LDL-C targets are not met [6].

North Dakota has a cardiovascular mortality rate that exceeds the national average in several rural counties, according to CDC Atlas data [14]. Rural patients often face additional barriers: fewer cardiology specialists, longer pharmacy travel distances, and lower rates of lipid panel monitoring. Telehealth prescribing and mail-order pharmacy fulfillment reduce some of those barriers. A 2023 analysis in JAMA Cardiology found that telehealth-initiated PCSK9 inhibitor prescribing produced equivalent 12-month LDL-C outcomes compared with in-person cardiology visits (mean LDL-C reduction 56 mg/dL vs. 58 mg/dL, P=0.41) [15].

Comparing Praluent to Other PCSK9 Inhibitors Available in North Dakota

Two other injectable lipid-lowering agents may be available in North Dakota with different cost profiles.

Evolocumab (Repatha, Amgen) is the other monoclonal antibody PCSK9 inhibitor and shares broadly similar clinical efficacy. FOURIER (N=27,564) showed evolocumab reduced major cardiovascular events by 15 percent over 2.2 years (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) [16]. Repatha's list price is comparable to Praluent. The two drugs are not interchangeable by pharmacists, but a prescriber may switch a patient between them if formulary differences create a meaningful cost advantage. Some ND commercial plans have placed one agent on a more favorable tier than the other.

Inclisiran (Leqvio, Novartis) is a small interfering RNA (siRNA) targeting PCSK9 mRNA. It is dosed as a subcutaneous injection in the office at month 0, month 3, and then every 6 months, which removes the at-home self-injection burden. ORION-10 (N=1,561) showed inclisiran reduced LDL-C by 52.3 percent vs. placebo at 510 days (P<0.001) [17]. Its billing pathway (physician-administered, potentially billed under medical benefit rather than pharmacy benefit) may create different cost-sharing under some ND plans. Patients whose pharmacy benefit denies Praluent should ask their cardiologist whether inclisiran billed under the medical benefit is a practical alternative.

Bempedoic acid (Nexletol) offers oral dosing and a list price lower than PCSK9 inhibitors, with an LDL-C reduction of approximately 18 percent as monotherapy [18]. It is not a PCSK9 inhibitor but may be an adjunct option for patients who cannot access or afford injectable agents.

How to Get a Praluent Prescription via Telehealth in North Dakota

Telehealth prescribing of Praluent is permitted in North Dakota for patients who meet FDA-label criteria. A telehealth provider must hold an active North Dakota medical license. The consultation must include a review of recent lipid panel results (typically within 6 to 12 months), documentation of current statin therapy and dose, confirmation of HeFH or ASCVD diagnosis, and a prescription with clear dosing instructions [3].

North Dakota does not require an in-person visit before a telehealth prescription is issued for a chronic disease medication such as a lipid-lowering agent. Patients should have their most recent lipid panel, statin prescription, and cardiologist or primary care records available for the telehealth visit to avoid delays in prior authorization submission.

Mail-order pharmacy fulfillment is available for Praluent in North Dakota. Patients with active prior authorization and a valid savings card can have prefilled pens shipped directly to their home, which is particularly valuable for patients in rural ND counties more than 60 miles from a specialty pharmacy.

Practical Steps Before Your First Fill

Confirm your diagnosis codes: ICD-10 E78.01 (familial hypercholesterolemia, heterozygous) or I25.10 (atherosclerotic heart disease of native coronary artery without angina pectoris) are the codes most commonly used on PA submissions. A missing or mismatched diagnosis code is among the most common causes of PA denial.

Request a 90-day supply: Most savings card programs and insurance plans allow 90-day fills at mail order, which reduces dispensing fees and simplifies the refill schedule for a drug dosed every two weeks.

Monitor LDL-C at 4 to 12 weeks after initiation: The prescriber should document the LDL-C response, typically a 45 to 60 percent reduction from baseline [2], both for clinical management and to support continued insurance coverage at the annual PA renewal. Failure to demonstrate LDL-C response at renewal can trigger non-renewal or a request to step down to a less costly agent.

If the 75 mg starting dose does not achieve an LDL-C below 70 mg/dL (the target for very high-risk ASCVD per ACC/AHA 2022 guidelines [6]), the label supports titration to 150 mg every two weeks at 4 to 8 weeks [3]. The savings card covers both dose levels.